Evogene (EVGN) Registration Filing summary

Company overview and business model

• Focuses on computational biology to accelerate life-science product development in human health, agriculture, and other sectors using AI-driven platforms.

• Operates through subsidiaries specializing in microbiome therapeutics, ag-chemicals, ag-biologicals, and bio-based industrial applications.

• Recent initiatives include ceasing medical cannabis operations, launching an AI-driven plant protein company, and expanding collaborations in probiotics and crop protection.

Financial performance and metrics

• Revenue rose to $914,000 in Q2 2024 and $5.1 million in H1 2024, up from $654,000 and $1.3 million in the same periods of 2023, driven by subsidiary deals and licensing.

• Net loss decreased to $6.0 million in Q2 2024 and $9.8 million in H1 2024, compared to $7.8 million and $14.8 million in 2023, due to higher revenues and lower expenses.

• Cash and cash equivalents as of June 30, 2024, were $9.5 million, with pro forma as adjusted cash of $26.4 million post-offering.

Use of proceeds and capital allocation

• Will receive up to $12.02 million from warrant exercises, intended for R&D, working capital, subsidiary investments, sales and marketing, and potential acquisitions.